TABLE 1.
Demographic data of participants.
| SILCODE | ADNI | |||||||
|---|---|---|---|---|---|---|---|---|
| NC | SCD | MCI | AD | NC | SCD | MCI | AD | |
| N | 215 | 194 | 153 | 92 | 197 | 191 | 158 | 104 |
| Age | 67.03 ± 6.18 | 66.84 ± 5.97 | 67.80 ± 9.86 | 68.87 ± 9.67 | 72.20 ± 8.86 | 72.36 ± 6.80 | 73.23 ± 7.39 | 74.86 ± 8.11 c ,** |
| Sex (M/F) | 85/130 | 74/120 | 79/74 | 39/53 | 78/119 | 84/107 | 91/67 b ,*** | 68/36 c ,*** |
| Education | 11.60 ± 3.81 | 11.69 ± 2.94 | 10.93 ± 4.12 | 10.59 ± 4.67 | 16.74 ± 2.32 | 16.85 ± 2.25 | 16.25 ± 2.42 | 15.38 ± 2.18 c ,** |
| MoCA‐B | 25.82 ± 2.86 | 26.01 ± 2.34 | 19.82 ± 3.9 b ,*** | 12.00 ± 5.17 c ,*** | / | / | / | / |
| MoCA | / | / | / | / | 26.19 ± 2.61 | 25.89 ± 2.49 | 22.35 ± 3.48 b ,*** | 17.06 ± 4.30 c ,*** |
| SCD‐9 | 3.59 ± 2.23 a ,*** | 5.57 ± 1.50 | 5.24 ± 1.92 b ,*** | 6.13 ± 2.05 c ,*** | / | / | / | / |
| MMSE | 28.57 ± 1.70 | 28.34 ± 1.65 | 24.42 ± 3.75 b ,*** | 17.83 ± 5.58 c ,*** | 28.98 ± 1.25 | 29.12 ± 1.12 | 27.33 ± 2.10 b ,*** | 22.90 ± 2.68 c ,*** |
| SUVR of AV45 | / | / | / | / | 1.104 ± 0.16 a ,* | 1.145 ± 0.192 | / | / |
| Follow‐up data | / | / | / | / | N = 79 | N = 66 | / | / |
| Visits | / | / | / | / | 3 (3–9) | 3 (3–9) | / | / |
| Duration (years) | / | / | / | / | 4.9 (0.5–10.3) | 4.2 (1.0–9.1) | / | / |
Note: Data are presented as mean ± SD.
Abbreviations: AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; ALPS, analysis along the perivascular space; AV45, florbetapir; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; MoCA‐B, Montreal Cognitive Assessment Basic; NC, normal control; SCD, subjective cognitive decline; SCD‐9, 9‐item subjective cognitive decline questionnaire; SD, standard deviation; SILCODE, Sino Longitudinal Study on Cognitive Decline; SUVR, standardized uptake value ratio.
a
NC versus SCD group.
b
SCD versus MCI group.
c
SCD versus AD group.
* P < 0.05, ** P < 0.01, *** P < 0.001.